Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Aug 16;14(8):e0221276.
doi: 10.1371/journal.pone.0221276. eCollection 2019.

Micro-costing and a cost-consequence analysis of the 'Girls Active' programme: A cluster randomised controlled trial

Joanna M Charles  1 , Deirdre M Harrington  2 , Melanie J Davies  2   3 , Charlotte L Edwardson  2 , Trish Gorely  4 , Danielle H Bodicoat  2 , Kamlesh Khunti  2   3 , Lauren B Sherar  5 , Thomas Yates  2 , Rhiannon Tudor Edwards  1
Affiliations
Randomized Controlled Trial

Micro-costing and a cost-consequence analysis of the 'Girls Active' programme: A cluster randomised controlled trial

Joanna M Charles et al. PLoS One. .

Abstract

Physical inactivity has been identified as a leading risk factor for premature mortality globally, and adolescents, in particular, have low physical activity levels. Schools have been identified as a setting to tackle physical inactivity. Economic evidence of school-based physical activity programmes is limited, and the costs of these programmes are not always collected in full. This paper describes a micro-costing and cost-consequence analysis of the 'Girls Active' secondary school-based programme as part of a cluster randomised controlled trial (RCT). Micro-costing and cost-consequence analyses were conducted using bespoke cost diaries and questionnaires to collect programme delivery information. Outcomes for the cost-consequence analysis included health-related quality of life measured by the Child Health Utility-9D (CHU-9D), primary care General Practitioner (GP) and school-based (school nurse and school counsellor) service use as part of a cluster RCT of the 'Girls Active' programme. Overall, 1,752 secondary pupils were recruited and a complete case sample of 997 participants (Intervention n = 570, Control n = 427) was used for the cost-consequence analysis. The micro-costing analysis demonstrated that, depending upon how the programme was delivered, 'Girls Active' costs ranged from £1,054 (£2 per pupil, per school year) to £3,489 (£7 per pupil, per school year). The least costly option was to absorb 'Girls Active' strictly within curriculum hours. The analysis demonstrated no effect for the programme for the three main outcomes of interest (health-related quality of life, physical activity and service use).Micro-costing analyses demonstrated the costs of delivering the 'Girls Active' programme, addressing a gap in the United Kingdom (UK) literature regarding economic evidence from school-based physical activity programmes. This paper provides recommendations for those gathering cost and service use data in school settings to supplement validated and objective measures, furthering economic research in this field. Trial registration: -ISRCTN, ISRCTN10688342.

PubMed Disclaimer

Conflict of interest statement

MJD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen, an advisory board member for Servier and as a speaker for Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International Inc. MJD has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim and Janssen. This does not alter our adherence to PLOS ONE policies on sharing data and materials. KK has served as a speaker/consultant for Amgen, AstraZeneca, Bayer, NAPP, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Berlin-Chemie AG / Menarini Group, Sanofi-Aventis and Servier. KK has received grants in support of investigator and investigator initiated trials from AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. KK has served on advisory boards for Amgen, AstraZeneca, Bayer, NAPP, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Berlin-Chemie AG / Menarini Group, Sanofi-Aventis and Servier. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Outside of the submitted work, JMC and RTE report funding from Public Health Wales during the conduct of the study. CE reports grants from National Institute for Health Research Public Health Research during the conduct of the study. DHB, TG, DMH, LS and TY all have nothing to declare.

References

    1. World Health Organisation Global Recommendations on Physical Activity for Health 2011 http://www.who.int/dietphysicalactivity/publications/physical-activity-r... Accessed 05 September 2017.
    1. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;38:247–257. - PubMed
    1. Public Health England. Health Survey for England 2015, Trend Tables. Health and Social Care Information Centre 2016. http://www.content.digital.nhs.uk/catalogue/PUB22610 Accessed 05 September 2017.
    1. Kids UA. Generation Active. 2015. http://www.ukactive.com/downloads/managed/ON02629_UK_Active_Kids_report_... Accessed 05 September 2017.
    1. Sport England. Sport England: Towards an Active Nation Strategy 2016–2021. 2016. https://www.sportengland.org/media/10629/sport-england-towards-an-active... Accessed 05 September 2017.

Publication types

MeSH terms

Associated data